Konstanze Döhner
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.
Scotch A, Kosiorek H, Scherber R, Dueck A, Slot S, Zweegman S, Boekhorst P, Commandeur S, Schouten H, Sackmann F, Fuentes A, Hernández-Maraver D, Pahl H, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto J, Ranta D, Roy L, Cahn J, Harrison C, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson P, Barbui T, Barosi G, Vannucchi A, Paoli C, Passamonti F, Andreasson B, Ferrari M, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian J, Zhang P, Gale R, Mesa R, Geyer H. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leuk Res 2017; 63:34-40.
14.10.2017Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.
14.10.2017Leuk Res 2017; 63:34-40
Scotch Allison H, Kosiorek Heidi, Scherber Robyn, Dueck Amylou C, Slot Stefanie, Zweegman Sonja, Boekhorst Peter A W Te, Commandeur Suzan, Schouten Harry, Sackmann Federico, Fuentes Ana Kerguelen, Hernández-Maraver Dolores, Pahl Heike L, Griesshammer Martin, Stegelmann Frank, Döhner Konstanze, Lehmann Thomas, Bonatz Karin, Reiter Andreas, Boyer Francoise, Etienne Gabriel, Ianotto Jean-Christophe, Ranta Dana, Roy Lydia, Cahn Jean-Yves, Harrison Claire N, Radia Deepti, Muxi Pablo, Maldonado Norman, Besses Carlos, Cervantes Francisco, Johansson Peter L, Barbui Tiziano, Barosi Giovanni, Vannucchi Alessandro M, Paoli Chiara, Passamonti Francesco, Andreasson Bjorn, Ferrari Maria L, Rambaldi Alessandro, Samuelsson Jan, Birgegard Gunnar, Xiao Zhijian, Xu Zefeng, Zhang Yue, Sun Xiujuan, Xu Junqing, Kiladjian Jean-Jacques, Zhang Peihong, Gale Robert Peter, Mesa Ruben A, Geyer Holly L
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
Geyer H, Kosiorek H, Dueck A, Scherber R, Slot S, Zweegman S, Te Boekhorst P, Senyak Z, Schouten H, Sackmann F, Fuentes A, Hernández-Maraver D, Pahl H, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto J, Ranta D, Roy L, Cahn J, Harrison C, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson P, Barbui T, Barosi G, Vannucchi A, Paoli C, Passamonti F, Andreasson B, Ferrari M, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian J, Zhang P, Gale R, Mesa R. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica 2016; 102:85-93.
18.08.2016Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
18.08.2016Haematologica 2016; 102:85-93
Geyer Holly L, Kosiorek Heidi, Dueck Amylou C, Scherber Robyn, Slot Stefanie, Zweegman Sonja, Te Boekhorst Peter Aw, Senyak Zhenya, Schouten Harry, Sackmann Federico, Fuentes Ana Kerguelen, Hernández-Maraver Dolores, Pahl Heike L, Griesshammer Martin, Stegelmann Frank, Döhner Konstanze, Lehmann Thomas, Bonatz Karin, Reiter Andreas, Boyer Francoise, Etienne Gabriel, Ianotto Jean-Christophe, Ranta Dana, Roy Lydia, Cahn Jean-Yves, Harrison Claire N, Radia Deepti, Muxi Pablo, Maldonado Norman, Besses Carlos, Cervantes Francisco, Johansson Peter L, Barbui Tiziano, Barosi Giovanni, Vannucchi Alessandro M, Paoli Chiara, Passamonti Francesco, Andreasson Bjorn, Ferrari Maria L, Rambaldi Alessandro, Samuelsson Jan, Cannon Keith, Birgegard Gunnar, Xiao Zhijian, Xu Zefeng, Zhang Yue, Sun Xiujuan, Xu Junqing, Kiladjian Jean-Jacques, Zhang Peihong, Gale Robert Peter, Mesa Ruben A
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Geyer H, Scherber R, Kosiorek H, Dueck A, Kiladjian J, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes A, Hernández-Maraver D, Döhner K, Harrison C, Radia D, Muxi P, Besses C, Cervantes F, Johansson P, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto J, Ranta D, Roy L, Cahn J, Maldonado N, Barosi G, Ferrari M, Gale R, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst P, Commandeur S, Schouten H, Pahl H, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi A, Passamonti F, Samuelsson J, Mesa R. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. J Clin Oncol 2015; 34:151-9.
23.11.2015Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
23.11.2015J Clin Oncol 2015; 34:151-9
Geyer Holly L, Scherber Robyn, Kosiorek Heidi, Dueck Amylou C, Kiladjian Jean-Jacques, Xiao Zhijian, Slot Stefanie, Zweegman Sonja, Sackmann Federico, Fuentes Ana Kerguelen, Hernández-Maraver Dolores, Döhner Konstanze, Harrison Claire N, Radia Deepti, Muxi Pablo, Besses Carlos, Cervantes Francisco, Johansson Peter L, Andreasson Bjorn, Rambaldi Alessandro, Barbui Tiziano, Bonatz Karin, Reiter Andreas, Boyer Francoise, Etienne Gabriel, Ianotto Jean-Christophe, Ranta Dana, Roy Lydia, Cahn Jean-Yves, Maldonado Norman, Barosi Giovanni, Ferrari Maria L, Gale Robert Peter, Birgegard Gunnar, Xu Zefeng, Zhang Yue, Sun Xiujuan, Xu Junqing, Zhang Peihong, te Boekhorst Peter A W, Commandeur Suzan, Schouten Harry, Pahl Heike L, Griesshammer Martin, Stegelmann Frank, Lehmann Thomas, Senyak Zhenya, Vannucchi Alessandro M, Passamonti Francesco, Samuelsson Jan, Mesa Ruben A
Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure
Schittenhelm M, Illing B, Ahmut F, Rasp K, Blumenstock G, Döhner K, Lopez C, Kampa-Schittenhelm K. Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure. PloS one 2013; 8:e80193.
27.11.2013Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure
27.11.2013PloS one 2013; 8:e80193
Schittenhelm Marcus, Illing Barbara, Ahmut Figen, Rasp Katharina Henriette, Blumenstock Gunnar, Döhner Konstanze, Lopez Charles D, Kampa-Schittenhelm Kerstin
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
Kampa-Schittenhelm K, Heinrich M, Akmut F, Rasp K, Illing B, Döhner H, Döhner K, Schittenhelm M. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol Cancer 2013; 12:46.
24.05.2013Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
24.05.2013Mol Cancer 2013; 12:46
Kampa-Schittenhelm Kerstin, Heinrich Michael Charles, Akmut Figen, Rasp Katharina Henriette, Illing Barbara, Döhner Hartmut, Döhner Konstanze, Schittenhelm Marcus
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
Krönke J, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk R, Döhner H, Späth D, Kapp-Schwörer S, Bullinger L, Teleanu V, Tschürtz F, Gaidzik V, Kühn M, Rücker F, Holzmann K, Paschka P, Döhner K. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013; 122:100-8.
23.05.2013Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
23.05.2013Blood 2013; 122:100-8
Krönke Jan, Kindler Thomas, Schittenhelm Marcus, Krauter Jürgen, Ganser Arnold, Göhring Gudrun, Schlegelberger Brigitte, Schlenk Richard F, Döhner Hartmut, Späth Daniela, Kapp-Schwörer Silke, Bullinger Lars, Teleanu Veronica, Tschürtz Florian, Gaidzik Verena I, Kühn Michael W M, Rücker Frank G, Holzmann Karlheinz, Paschka Peter, Döhner Konstanze
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
Kampa-Schittenhelm K, Heinrich M, Akmut F, Döhner H, Döhner K, Schittenhelm M. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer 2013; 12:19.
07.03.2013Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
07.03.2013Mol Cancer 2013; 12:19
Kampa-Schittenhelm Kerstin, Heinrich Michael Charles, Akmut Figen, Döhner Hartmut, Döhner Konstanze, Schittenhelm Marcus
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Fröhling S, Jiang J, Schittenhelm M, Lee B, Griffin J, Stone R, Heinrich M, Deininger M, Druker B, Golub T, Teckie S, Ebert B, Scholl C, Levine R, Loriaux M, Boggon T, Bernard O, Berger R, Döhner H, Döhner K, Gilliland D. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007; 12:501-13.
01.12.2007Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
01.12.2007Cancer Cell 2007; 12:501-13
Fröhling Stefan, Jiang Jingrui, Schittenhelm Marcus, Lee Benjamin H, Griffin James D, Stone Richard M, Heinrich Michael C, Deininger Michael W, Druker Brian J, Golub Todd R, Teckie Sewit, Ebert Benjamin L, Scholl Claudia, Levine Ross L, Loriaux Marc, Boggon Titus J, Bernard Olivier A, Berger Roland, Döhner Hartmut, Döhner Konstanze, Gilliland D Gary